Longterm Control of Advanced and Recurrent Gastric Cancer (ARGC) by S-1

Gastric Cancer - Germany
doi 10.1007/s10120-003-0217-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Nature

Related search

S-1 in the Treatment of Advanced and Recurrent Gastric Cancer: Current State and Future Prospects

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2003English

S-1 With Leucovorin and Oxaliplatin for Advanced Gastric Cancer

The Lancet Oncology
Oncology
2016English

Phase I/Ii Study of S-1 Combined With Paclitaxel in Patients With Unresectable and/or Recurrent Advanced Gastric Cancer

British Journal of Cancer
Cancer ResearchOncology
2006English

Efficacy and Safety of Oxaliplatin, Bevacizumab and Oral S-1 for Advanced Recurrent Colorectal Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2016English

Combination Therapy With Docetaxel and S-1 as a First-Line Treatment in Patients With Advanced or Recurrent Gastric Cancer: A Retrospective Analysis

World Journal of Surgical Oncology
SurgeryOncology
2010English

Efficacy of Paclitaxel and S-1 in a Patient With Advanced Pseudomyxoma Peritonei Concomitant With Gastric Cancer

General Medicine: Open Access
2013English

Randomized Phase II Trial of First-Line Treatment With Tailored Irinotecan and S-1 Therapy Versus S-1 Monotherapy for Advanced or Recurrent Gastric Carcinoma (JFMC31-0301)

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2011English

Weekly Paclitaxel as Second-Line Chemotherapy for Advanced or Recurrent Gastric Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2006English

Successful Treatment of Advanced Gastric Cancer With TS-1 Followed by Curative Gastrectomy

Japanese Journal of Gastroenterological Surgery
SurgeryGastroenterology
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy